Enarodustat
ApprovedSmall molecule
Enarodustat is one of 71 small molecule programs targeting Anemia. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Enarodustat
SShenzhen Salubris Pharmaceuticals Co., Ltd.
Approved
Aranesp
AmgenPreclinical
Uloric
TakedaPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Genotropin
EMD SeronoPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enarodustat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details